Search:

Filter:

Post type:

Sort:

Key takeaways from PSM’s Axios event: Examining risk and regulation in the compounded GLP-1 landscape

August 11, 2026

SAFE Drugs Act sponsor Rep. Rudy Yakym (R-IN), Rep. Nikki Budzinski (D-IL), leading obesity medicine specialist Dr. Scott Kahan, and PSM Executive Director Shabbir Imber Safdar. delivered a clear message: Compounded substances are not the same as FDA-approved medications, and treating them as such undermines patients’ safety.

Judgment, USA v Frank Incognito

August 11, 2026

United States District Court District of New Jersey USA v Frank Incognito Judgment  Filed July 2026 Read the document.

Plea Agreement, USA v Frank Incognito

August 11, 2026

United States District Court District of New Jersey USA v Frank Incognito Plea Agreement  Filed February 2026 Read the document.

Information, USA v Frank Incognito

August 10, 2026

United States District Court District of New Jersey USA v Frank Incognito Information Filed February 2026 Read the document.

Plea Agreement, USA v Bryce Cleveland

August 10, 2026

United States District Court Western District of Virginia USA v Bryce Cleveland Plea Agreement Filed July 2026 Read the document.

Indictment, USA v Bryce Cleveland

August 10, 2026

United States District Court Western District of Virginia USA v Bryce Cleveland Indictment Filed July 2024 Read the document.

August 3, 2026: Peptide vendor sentenced to six years for “incredible trail of harm”

August 4, 2026

The man was sentenced to six years for deceptively marketing “research use only” chemicals, which the judge said left “an incredible trail of harm.”

PSM joins PSI, Rx360 and PDSA in letter urging FDA to protect the traceable drug supply

July 29, 2026

PSM joined three other organizations for a sign-on letter explaining our concerns that unrestricted mass compounding increases the untraceable drug supply. An explosion of 503B compounding of these three substances, semaglutide, tirzepatide, and liraglutide, would dramatically increase the compounded medicine supply which is not serialized, and therefore, not traceable.

July 27, 2026: FDA peptide panel narrowly votes to add unapproved drugs to compounding list

July 29, 2026

FDA’s Pharmaceutical Compounding Advisory Committee voted to add six of seven peptides to the 503A Bulk Drug Substance List, despite FDA scientists recommending against all of them because of limited evidence of their safety and effectiveness.

PSM submits comment supporting the continued exclusion of GLP-1s from the 503B Bulks List

July 28, 2026

PSM supports the FDA’s proposal, which will help protect patient safety and the integrity of the drug approval process.